knowledge -WSS

knowledge

author：entertainment 2025-10-01 02:14:50 - browse：4

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for the last day here.

ASCO is more than half done. There is free coffee on the exhibit floor. One booth barista said their team had made 1,400 espressos in a day. Everyone’s perspective is alternating between two verses from Smashing Pumpkins, who are, lest you forget, a Chicago band. “Today is the greatest day I’ve ever known.” Also: “I’ll burn my eyes out before I get out.”

What if sometimes cancer doctors could give less medicine?

Are cancer drugs more likely to be cures? Or could they instead turn cancer into a chronic disease, in which medicines keep tumors in check but patients have to deal with their side effects, both physical and financial, for the rest of their lives.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

WSS

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

How to increase colonoscopy rates? Looks like an AI can help

J&J lung cancer data amount to new salvo against AstraZeneca

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ADCs take center stage as promising cancer treatments

Study on Amgen’s bispecific immunotherapy produces positive data

entertainment

knowledge

What if sometimes cancer doctors could give less medicine?

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Summit: How researchers deal with rejection

Tori Bowie and the unacceptable rates of Black maternal death

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Alkermes shareholders re

Ionis drug prevents swelling attacks due to hereditary angioedema

State Dept. review finds Biden bears some blame for Afghanistan failures

Smaller biotechs seek to piggyback on weight loss drug boom

In age of alternative facts, a scholarly course on calling out crap

Roche drug slashes death risk in early

hotspot

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO: AstraZeneca says CAR

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Readout: Friday, Oct. 20 biotech updates

Cord blood banking comes at a high cost to babies

focus

Wikipedia

leisure time

explore